IL-1 receptor signaling in the basolateral amygdala modulates binge-like ethanol consumption in male C57BL/6J mice by Marshall, S. Alex et al.
IL-1 receptor signaling in the basolateral amygdala modulates 
binge-like ethanol consumption in male C57BL/6J mice
S. Alex Marshall, PhD1,2, John D. Casachahua, MS1,2, Jennifer A. Rinker, PhD1,2, Allyson K. 
Blose1, Donald T. Lysle, PhD1,2, and Todd E. Thiele, PhD1,2
1Department of Psychology & Neuroscience, The University of North Carolina, Chapel Hill, NC 
27599
2Bowles Center for Alcohol Studies; The University of North Carolina, Chapel Hill, NC 27599
Abstract
Proinflammatory cytokines have been implicated in alcohol-induced neurodegeneration, but the 
role of the neuroimmune system in alcohol related behaviors has only recently come to the 
forefront. Herein, the effects of binge-like drinking on IL-1β mRNA and immunoreactivity within 
the amygdala were measured following the “drinking in the dark” (DID) paradigm, a model of 
binge-like ethanol drinking in C57BL/6J mice. Moreover, the role of IL-1 receptor signaling in the 
amygdala on ethanol consumption was assessed. Results indicated that a history of binge-like 
ethanol drinking promoted a significant increase of IL-1β mRNA expression within the amygdala, 
and immunohistochemistry analyses revealed that the basolateral amygdala (BLA), but not central 
amygdala (CeA), exhibited significantly increased IL-1β immunoreactivity. Fluoro-Jade® C 
labeling indicated that multiple cycles of the DID paradigm were not sufficient to elicit neuronal 
death. Bilateral infusions of IL-1 receptor antagonist (IL-1Ra) reduced ethanol consumption when 
infused into the BLA but not the CeA. These observations were specific to ethanol drinking as the 
IL-1Ra did not alter either sucrose drinking or open-field locomotor activity. The current findings 
highlight a specific role for IL-1 receptor signaling in modulating binge-like ethanol consumption 
and indicate that proinflammatory cytokines can be induced prior to dependence or any evidence 
of neuronal cell death. These findings provide a framework in which to understand how 
neuroimmune adaptations may alter ethanol consumption and therein contributing to alcohol 
abuse.
1. Introduction
Binge drinking is a prevalent problem within the US, and repeated bouts of high blood 
alcohol concentrations can fundamentally change normal neurobiological functions (CDC, 
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2013; Gunzerath et al., 2011). These neuroplastic changes are thought to be one of the 
underlying mechanisms that lead to alcohol use disorders (AUDs) (Der-Avakian and 
Markou, 2012). One such system altered by alcohol abuse that has recently emerged as an 
area of interest is the neuroimmune system (Crews et al., 2011; Hutchinson and Watkins, 
2014). Studies of brains from people with a history of alcohol abuse show increased 
microglial activation and proinflammatory cytokines such as IL-1β (He and Crews, 2008; 
Zou and Crews, 2012). Pre-clinical studies concurring with this phenomenon have mainly 
focused on characterizing alcohol-induced neuroimmune responses in relation to cellular 
damage (Crews and Vetreno, 2014; Marshall et al., 2013) or the molecular mechanisms that 
underlie the initial immune response (Fernandez-Lizarbe et al., 2013). In particular, IL-1β 
has been shown to be upregulated in the CNS after various AUD models (Lippai et al., 
2013; Qin et al., 2008). However, the contributions of neuroimmune responses to the 
modulation of ethanol consumption have been relatively ignored, especially in the transition 
between alcohol abuse and alcohol dependence. This study utilizes the “drinking-in-the-
dark” paradigm (DID) because it is uniquely suited to study neuroadaptations that occur 
during the transitory window between excessive ethanol consumption prior to dependence in 
rodents (Rhodes et al., 2005; Thiele and Navarro, 2014).
Studies focused on the alcohol-related behavioral implications of the immune system have 
shown that modulation of the system alters ethanol consumption. In general, immune 
activating compounds increase ethanol consumption; whereas, anti-inflammatory agents 
reduce ethanol intake (Bell et al., 2013; Blednov et al., 2011). For example, peripheral 
administration of lipopolysaccharide, an inflammatory agent, resulted in prolonged 
increased voluntary ethanol consumption (Blednov et al., 2011), but the specific molecular 
mechanisms underlying these responses are still elusive as lipopolysaccharide can alter a 
bevy of cytokines and chemokines (Qin et al., 2007; Turrin et al., 2001). Moreover, it is 
unclear if reduced consumption is caused by peripheral or CNS actions of immune 
modulation. The present study specifically assessed the role of IL-1 receptor signaling by 
examining IL-1β, a pro-inflammatory cytokine, changes induced by binge-like ethanol 
drinking and then blocking IL-1 receptor signaling by intracranial site-specific infusions of 
IL-1 receptor antagonist (IL-1Ra).
Cytokines are more than immunomodulators and have been increasingly implicated in CNS 
actions including complex behaviors like addiction (Coller and Hutchinson, 2012). IL-1β 
has come to the forefront as a key player in other behavioral phenotypes underlying AUDs 
including depression and pain disorders (Egli et al., 2012; Markou et al., 1998). Its signaling 
has been implicated in a variety of neuroplastic events in other maladaptations including 
anxiety and emotional disorders (Jones et al., 2015; Wohleb et al., 2014). The specific 
contribution of IL-1β within the CNS to AUDs has not been determined, but modulation of 
the IL-1 system through peripheral IL-1Ra injections has been shown to decrease alcohol-
induced sedation, motor impairment, as well as ethanol consumption (Lippai et al., 2013; 
Wu et al., 2011). Moreover, genetic polymorphisms of IL-1 have been found in alcohol-
dependent patients compared with healthy controls (Liu et al., 2009), but deletion of the 
gene that encodes IL-1Ra reduced ethanol preference and consumption in transgenic mice 
(Blednov et al., 2012) . While these studies suggest a link between IL-1 signaling and 
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ethanol consumption, the conflicting findings and whether these effects are from peripheral 
or CNS contributions of IL-1 receptor signaling are not known.
Although the neurocircuitry that modulates ethanol consumption is complex, the present 
study focuses on the role of IL-1 receptor signaling within the amygdala. Amygdalar IL-1 
receptor signaling is associated with increased anxiety, which is believed to be a potential 
underlying factor in ethanol consumption and craving (Chiu et al., 2014; Fox et al., 2007). 
Furthermore, neuropeptides like corticotrophin releasing factor (CRF) and neuropeptide Y 
(NPY), both of which modulate stress and anxiety, can modulate IL-1β concentrations 
(Ferreira et al., 2010; Gilpin et al., 2015; Kageyama et al., 2010; Rivest and Rivier, 1994). 
Our laboratory and others have previously shown that manipulating both CRF and NPY 
signaling within the amygdala and extended amygdala modulates binge-like ethanol 
consumption in mice (Correia et al., 2015; Lowery-Gionta et al., 2012; Pleil et al., 2015). 
Together these findings indicate a potential interplay between IL-1 signaling and ethanol 
consumption within the amygdala.
Given the link between IL-1 receptor signaling and CRF activity, and the known role of 
CRF in modulating binge-like ethanol drinking, we hypothesized that IL-1 receptor activity 
in the amygdala also modulates binge-like drinking and that it is not solely associated with 
alcohol-induced neurodegeneration. The current experiments tests these hypotheses by 
determining: a) the effects of binge-like drinking on IL-1β immunoreactivity and mRNA 
expression, b) whether ethanol-induced neuroimmune activity occurs independent of 
neurodegeneration, and finally c) the effects of blocking of IL-1 receptor signaling on 
ethanol consumption.
2. Methods
2.1 Animals
Male C57BL /6J 6-8 weeks old mice (Jackson Laboratories; Bar Harbor, ME) were 
individually housed in a reversed 12:12 hour light:dark cycle vivarium maintained at 22°C. 
During experiments, animals had ad libitum access to Prolab® RMH 3000 (Purina 
LabDiet®; St. Louis, MO) or Teklad Diet® 2920X (Harlan Laboratories Inc.; Indianapolis, 
IN) and water unless otherwise indicated. All animals were given at least a week to 
acclimate to the environment before experimentation. The procedures used in this study 
were all approved by the University of North Carolina Institutional Animal Care and Use 
Committee and followed the Guidelines for the Care and Use of Laboratory Animals.
2.2 “Drinking in the Dark” Procedures
Binge drinking was modeled using a 4 day DID paradigm as previously described (Rhodes 
et al., 2005). Briefly, home cage water bottles were removed, and mice were allotted two 
hour access to a single bottle of 20% (v/v) ethanol solution or a control solution of either 3% 
(w/v) sucrose or water three hours into the dark cycle. On the fourth day, also called the test 
day, consumption (g/kg) was measured for four hours. Each DID cycle was separated by 
three days for mice undergoing multiple 4-day DID cycles.
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Tail blood samples (≈60μL) were taken immediately following the DID procedure to 
determine blood ethanol concentration (BEC) except in the qRT-PCR experiment. For 
mRNA studies, trunk blood samples were taken in the group immediately euthanized 
following the DID cycle rather than tail vein samples. The groups euthanized 1 day or 7 
days after DID did not have tail blood samples taken to avoid any restraint stress associated 
with tail blood collection, which has previously been shown to alter IL-1β mRNA 
expression (Minami et al., 1991). Blood samples collected were centrifuged to obtain serum 
samples and run in duplicate with the AM1 Alcohol Analyzer (Analox, London, UK) for 
BEC determination (mg/dL).
2.3 qRT-PCR
Mice used in PCR studies experienced one 4-day DID cycle receiving either ethanol or 
water. Ethanol and water animals were further divided by euthanasia timepoint (0, 1 or 7 
days post DID; Ethanol n= 7-10/subgroup; H2O n= 6-10/subgroup). Following rapid 
decapitation, brains were extracted, flash frozen in isopentane, and stored at −80°C. 
Cylindrical punches of the amygdala (1mm x 1mm) were harvested and immediately 
submerged in RNALater Ice® (Ambion; Carlsbad, CA), according to manufacturer 
instructions. Amygdalar tissue punches were manually homogenized in Tri-Reagent (1ml/
50-100mg tissue, Molecular Research Center, Inc.; Cincinnati, OH) with a glass dounce 
tissue grinder and briefly sonicated. RNA was separated using 1-bromo-3-chloropropane 
(Molecular Research, Inc.) and purified using isopropanol. AdvantageTM RT-for-PCR kit 
(Clontech; Mountain View, CA) was used to create cDNA samples via reverse transcription. 
Samples of cDNA were analyzed using the UNC Animal Clinical Chemistry and Gene 
Expression Laboratories similar to protocols previously reported (Jones et al., 2015; Kim et 
al., 2002). The nucleotide sequences of the PCR primers and fluorogenic probes were 
developed by UNC Animal Clinical Chemistry and Gene Expression Laboratories. The 
nucleotide sequences of the PCR primers and fluorogenic probes used for the IL-1β and β-
actin genes are as follows. : IL-1β forward: 5’-AAT TTC TTG CAG CCG GAG CA-3’, 
reverse: 5’-AGG CGG AGG AAG TAT TCT TC-3’, probe: 5’-FCC AGC AAC CTC AGC 
CGG TTC TGA Q-3’; β-actin forward: 5’-CTG CCT GAC GGC CAG GTC-3’, reverse: 5’-
CAA GAA GGA AGG CTG GAA AAG A-3’, probe: 5’-FCA CTA TTG GCA ACG AGC 
GGT TCC GQ-3’. . Measurements were normalized to water groups as previously described 
and are expressed as fold change (Kim et al., 2002) .
2.4 Tissue Processing
Mice used in all other experiments were overdosed with a 0.15mL intraperitoneal (ip) 
injection of an anesthetic cocktail of ketamine (66.67mg/mL) and xylazine (6.67mg/mL) in 
0.9% saline. Animals were then transcardially perfused with 0.1M phosphate buffer saline 
(PBS; pH=7.4) and 4% paraformaldehyde in PBS (pH=7.4). Extracted brains were postfixed 
in paraformaldehyde for 24 hours and sectioned coronally at 40μm using a vibratome (Leica 
VT1000S; Wetzlar, Germany). Sections were collected in a 1:4 series for both 
immunohistochemistry (IHC) and Fluoro-Jade C (FJC) processing and stored in 
cryopreserve at −20°C.
Marshall et al. Page 4
Brain Behav Immun. Author manuscript; available in PMC 2017 January 01.
Author M
anuscript
Author M
anuscript
Author M
anuscript
Author M
anuscript
2.5 Immunohistochemistry & Immunoreactivity Quantification
Animals used for IHC analysis underwent one or three, 4-day cycles of DID receiving either 
ethanol or sucrose or 3 cycles with water and were euthanized immediately at the end of 
their final cycle (Ethanol n= 9/subgroup; Sucrose n= 9-10/subgroup; H2O n= 9). Every 
fourth section collected was used for IL-1β immunoreactivity detection. Free floating 
sections were rinsed in 0.1M PBS before endogenous peroxidases were quenched with 0.6% 
H2O2. After serial PBS washes, nonspecific binding was blocked using rabbit serum (PBS/
0.1% triton-X/3% rabbit serum; Vector Laboratories; Burlingame, CA). Sections were then 
incubated in goat IL-1β primary antibody (1:1000; R&D Systems; Minneapolis, MN) for 48 
hours at 4°C. After serial washes in rabbit serum to remove the primary, incubation in 
biotinylated rabbit anti-goat secondary antibody, avidin-biotin-peroxidase complex (ABC 
elite kit, Vector Labs), and the chromagen, 3,3’-diaminobenzidine tetrahydrochloride 
(Polysciences; Warrington, PA) were used for detection of IL-1β. Sections were then 
mounted onto glass slides and coverslipped with SHUR/Mount™ (Triangle Biomedical 
Sciences; Durham, NC).
Images of slides were taken with a Zeiss Axio Zoom V16 macroscope (Jena, Germany) 
installed on an HP Z820 Workstation at 100x magnification. Slide images were coded to 
ensure that the experimenter was blind to treatment conditions during quantification. The 
basolateral amygdala (BLA) and the central nucleus of the amygdala (CeA) were separately 
traced on sections between Bregma −0.70mm and −2.06mm (Paxinos and Franklin, 2004). 
IL-1β immunoreactivity was measured using Zen Pro 2012. Immunopositive pixels were 
determined by optical density from experimenter determined threshold so that 
immunoreactivity is expressed as percent area (immunoreactive positive area/total area of 
region of interest).
2.6 Fluoro-Jade C & Quantification
FJC is a method of assessing neurodegeneration comparable to amino-cupric silver staining 
(Schmued et al., 2005). This staining was performed on animals following one or three, 4-
day DID cycles and were euthanized immediately following the final DID cycle (Ethanol n= 
8-9/subgroup; Sucrose n=6-7/subgroup; H2O n=10). FJC processing was performed in 
accordance with manufacture instructions (Millipore, Billerica, MA) similar to previously 
published methods (Liput et al., 2013; Qin and Crews, 2012b). Briefly, every fourth section 
was mounted on Superfrost-Plus slides (Fisher Scientific, Pittsburgh, PA). After drying 
overnight in a 37°C incubator, sections were rehydrated with the following steps: 5 min in 
1% sodium hydroxide/ 80% ethanol; 2 min in 70% ethanol; 2 min ddH2O. After 
rehydration, slides were incubated in 0.06% potassium permanganate for 10 min while 
gently shaking and then rinsed in ddH2O for 2 min. Sections were then stained with 0.001% 
(w/v) FJC in 0.1% (v/v) acetic acid for 20 min. Finally residual FJC was removed by rinses 
(3 × 1 min; ddH2O). Slides were allowed to dry overnight and coverslipped using SHUR/
Mount™. FJC+ cells within the amygdalar subregions (Bregma −0.70mm and −2.06mm) 
were quantified at 200x using an Olympus BX-51 microscope (Center Valley, PA) and 
expressed as cell/section.
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2.7 Surgeries & IL-1Ra Intervention
Animals used to manipulate IL-1 receptor signaling underwent the 4-day DID procedure 
prior to surgery. For cannulae placement surgery, animals were anesthetized using a cocktail 
of xylazine (10mg/kg) and ketamine (100mg/kg) delivered ip (1.5mL/kg). Bilateral 26-G 
guide cannulae (Plastics One; Roanoke, VA) were aimed at the BLA (AP:−1.22, ML:±3.01, 
DV: −4.75) or the CeA (AP:−1.06, ML:±2.50, DV: −4.64) using an Angle IITM Stereotax 
(Leica Instruments, Buffalo Grove, IL) (Paxinos and Franklin, 2004). After a week of 
recovery, animals were subjected to the DID procedure again. On the test day, before 
alcohol access, 0.9μg of IL-1Ra (GenScript; Piscataway, NJ) dissolved in 0.9% saline 
(3mg/mL) or saline alone were infused at a rate of 0.15μL/min for two minutes using a 
Hamilton syringe (Reno, NV) attached to a Harvard Apparatus PHD 2000 infusion pump 
(Holliston, MS) similar to previous studies (Lowery-Gionta et al., 2012). Injectors were left 
in the guide cannulae for an additional 3 minutes to allow proper diffusion. All studies 
involving IL-1Ra used Latin-Square designs so that each mouse was dosed with both IL-1Ra 
and saline in a counterbalanced order for ethanol (BLA n=12; CeA n= 14) or sucrose (BLA 
n=13). At the conclusion of all behavioral analyses injection placements were histologically 
verified using an identical volume of Alcian blue dye (0.3μL/injection site) as the IL-1Ra 
experiments.
2.8 Open Field Tests
After a week of recovery, mice used in the sucrose test were then split into two groups 
receiving microinfusions in the BLA, as previously described, of either IL-1Ra (n=7) or 
saline (n=6) and subjected to open-field locomotor activity tests to assess the effects of 
IL-1Ra on general locomotor activity as well as its anxiolytic properties (Prut and Belzung, 
2003). Following microinfusions, mice were placed into an open-field arena identical to 
previous descriptions (Cox et al., 2013; Fee et al., 2004). Briefly, animal movement was 
tracked using the VersaMax® software program (AccuScan Instruments, Inc., Columbus, 
OH) over a two hour period with fifteen minute bin outputs using VersaDat® Version 4.00 
(AccuScan Instruments, Inc.). Total distance traveled was measured to assess the effect of 
IL-Ra on locomotor activity; whereas center distance and center time were recorded to 
determine the anxiolytic effects of IL-1Ra (Prut and Belzung, 2003).
2.9 Statistical Analysis
Prism Version 5.0 (GraphPad Software, Inc. La Jolla, Ca) was used to analyze and graph all 
data reported herein. Two-way analyses of variance (ANOVAs) were used to determine the 
effect of treatment and time for IL-1β mRNA expression and behaviors within the open-field 
test (OFT). However, one-way ANOVAs were used to assess data collected from both the 
BLA and the CeA for immunoreactivity of IL-1β and counts of FJC+ cells as well as to 
compare ethanol consumption in different cohorts of animals. Ethanol consumption, BECs, 
and sucrose consumption following IL-Ra manipulation were compared using a two-way 
(drug x order of drug presentation) repeated measures (RM) ANOVA. Bonferroni posthoc 
tests or t-tests were only conducted if a significant interaction or main effect of treatment 
was observed. All data are reported as the mean ± standard error of the mean and considered 
significant if p<0.05, two-tailed.
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3. Results
3.1 Binge-Like Ethanol Consumption Increased IL-1β mRNA expression
Animals used in the qRT-PCR experiment had a grand mean ethanol consumption of 
4.8±0.16g/kg. The BECs from the group immediately euthanized averaged 
106.5±16.5mg/dL. A one-way ANOVA indicated no significant differences in consumption 
between animals used at different time-points ([F(2,21)=0.07, p=0.93]; Table 1). Ethanol 
exposure resulted in increased IL-1β mRNA in the amygdala by approximately 6-fold 
compared with the water drinking control group. A two-way ANOVA revealed a main effect 
of binge-like ethanol versus water consumption history [F(1,43)=19.33, p<0.001] but no 
effect of time of abstinence after DID [F(2,43)=0.00, p=0.99] or an interaction [F(2,43)=0.01, 
p=0.99]. Collapsing across time, a posthoc t-test indicated a significant increase of IL-1β 
mRNA in mice that consumed ethanol compared with water [t(48)=4.21, p<0.001] (Figure 
1). Importantly, a two-way ANOVA showed no differences in the crossing point of the 
housekeeping gene, β-actin, between the water group and animals that received ethanol 
(Table 2).These indicate that a short history of binge-like ethanol drinking promotes 
increased IL-1β expression that persists up to a week following binge-like consumption.
3.2 Binge-Like Ethanol Consumption Increased IL-1β Immunoreactivity
Animals used in the IL-1β immunoreactivity experiment had a grand mean ethanol 
consumption of 4.5±0.35g/kg and BEC of 70.4±11.4mg/dL. T-tests indicated no significant 
differences in ethanol consumption [t(17) =0.02, p=0.98] or BECs [t(17) =1.57, p=0.14] 
between animals that had one or three 4-day DID cycles (Table 1). Photomicrographs 
indicated IL-1β positive cells were apparent in the amygdala of both ethanol and control 
animals as previously shown in rodents (Figure 2) (Ericsson et al., 1995; Yabuuchi et al., 
1994). Binge-like ethanol drinking resulted in an increased IL-1β immunoreactivity 
compared with the water drinking control group in the BLA (Figure 2A). A one-way 
ANOVA revealed a main effect of group [F(2,23)=4.25, p=0.03]. Posthoc Bonferroni tests 
indicated a significant increase of IL-1β immunoreactivity in mice that experienced 3 cycles 
of DID compared with water drinking control mice (p<0.05). In the CeA, a one-way 
ANOVA did not reach statistical significance ([F(2,23)=0.95, p=0.40]; Figure 2C). These 
data indicate that a history of binge-like ethanol drinking promotes increased IL-1β 
immunoreactivity specifically in the BLA and not the CeA. Importantly, no difference was 
indicated by one-way ANOVAs between animals drinking water versus sucrose in the BLA 
[F(2,24)=0.05, p=0.95] or the CeA [F(2,24)=0.36, p=0.70] (Figure 2B,D), suggesting that 
increased IL-1β was specific to ethanol consumption.
3.3 Binge-Like Ethanol Drinking Elicits Neuroimmune Responses Independent of 
Neurodegeneration
Neuroimmune responses are often elicited by neurodegeneration, so FJC was used to assess 
potential ethanol-induced damage stemming from binge-like ethanol intake. Animals used to 
assess neurodegeneration had a grand mean ethanol consumption of 4.5±0.28g/kg and BEC 
of 71.9±16.25mg/dL (Table 1). Very few FJC+ cells were observed in the amygdala of 
animals that received water (Figure 3E) or following 1 or 3, 4-day cycles of binge-like 
ethanol drinking as evident in the photomicrographs (Figure 3F,G); however, an LPS treated 
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positive control was run in conjunction to ensure the FJC protocol was successful (Figure 
3H). One-way ANOVAs indicated no significant effect of ethanol or sucrose drinking 
compare with water consumption in either the BLA [F(2,24)=0.22, p=0.81; F(2,20)=0.88, 
p=0.43] (Figure 3A,B) or the CeA [F(2,24)=0.79, p=0.46; F(2,20)=1.31, p=0.29] (Figure 3C, 
D).
3.4 IL-1Ra Infusion in BLA Reduced Binge-Like Ethanol but not Sucrose Consumption
There was an 87% success rate in bilateral cannula placements. Six animals whose cannulas 
were not within the BLA or CeA were removed from analyses. With respect to the BLA, a 
two-way RM ANOVA (drug x order of drug presentation) on ethanol consumption indicated 
a main effect of drug treatment [F(1,11)=12.30, p=0.005] but no main effect of drug order 
[F(1,11)<0.01, p=0.97] or interaction between order and treatment [F(1,11)=4.64, p=0.06] 
(Figure 4A). Likewise, a two-way RM ANOVA (drug x order of drug presentation) of BECs 
indicated a main effect of drug treatment [F(1,11)=15.28, p=0.002] but no main effect of drug 
order [F(1,11)=0.42, p=0.53] or interaction between order and treatment [F(1,11)=0.51, 
p=0.49] (Figure 4B). However, a two-way RM ANOVA of binge-like ethanol consumption 
in the CeA experiment revealed no interaction [F(1,13)=1.32, p=0.27] or main effects of 
IL-1Ra [F(1,13)=0.63, p=0.44] or order of drug treatment [F(1,13)=0.07, p=0.80] (Figure 4C). 
No effect of IL-1Ra administration in the CeA [F(1,13)=1.03, p=0.33], order of treatment 
[F(1,13)=1.02, p=0.33], or interaction [F(1,13)=2.79, p=0.12] was determined using a two-way 
RM ANOVA examining BECs (Figure 4D). The effects of manipulating IL-1 receptor 
signaling via IL-1Ra in the BLA was specific to ethanol consumption as a two-way RM 
ANOVA comparing groups that consumed sucrose did not indicate any significant effect of 
the IL1Ra [F(1,12)=2.12, p=0.17], drug presentation order [F(1,12)=2.33, p=0.15], or any 
interaction [F(1,12)=0.18, p=0.68] (Figure 5A).
3.5 IL-1Ra Infusion in BLA had No Effects in Open-Field Test
Reduced ethanol consumption caused by IL-1Ra manipulation in the BLA is not likely due 
to IL-Ra induced changes in locomotor as a two-way repeated measures ANOVA only 
indicated a significant main effect of time [F(7,77)= 42.20, p<0.001] but not treatment 
[F(1,77)= 0.11, p=0.74] or any interaction [F(7,77)=1.47, p=0.19] on total distance traveled 
(Figure 5B). Moreover, no significant main effects or interactions were observed after T-
tests of total time spent [t(11) =0.28, p=0.79] or distance traveled [t(11) =1.13, p=0.28] in the 
center of the open field arena suggesting that intra-BLA IL-1Ra does not induce an 
anxiolytic state which would also affect ethanol consumption (Figure 5C, 5D).
4. Discussion
Alcohol’s effects on the neuroimmune system has usually been studied in relation to 
alcohol-induced neurodegeneration, but the current study shows that alcohol-induced 
changes to the neuroimmune system have behavioral implications independent of neuronal 
loss. This work highlights a role of IL-1 receptor signaling in a site-specific manner within 
the CNS. The data herein provides evidence that: a) binge-like ethanol consumption 
increased IL-1β mRNA expression in the amygdala and immunoreactivity in the BLA, b) 
modulation of the neuroimmune system occurs independently of neuronal cell death, and c) 
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inhibition of IL-1 receptor signaling within the BLA results in reduced binge-like ethanol 
consumption. Cumulatively these studies suggest that alcohol-induced increases of IL-1β in 
the BLA promote continued binge-like ethanol drinking which can be blunted with blockade 
of IL-1Ra in the BLA.
Manipulation of the immune system effects on ethanol consumption are not completely 
novel (Blednov et al., 2011; Blednov et al., 2012), but the present study not only identifies a 
direct role of a specific cytokine system, IL-1, but more importantly it shows IL-1 receptor 
signaling affects ethanol consumption via CNS actions rather than as a byproduct of 
peripheral actions. The importance of the IL-1 system in ethanol consumption has 
previously been highlighted by gene array studies and further validated with behavioral 
experiments in knockout mice (Blednov et al., 2012; Mulligan et al., 2006). However, global 
knockouts and peripheral manipulations lack site-specificity and cannot separate the 
developmental role of the cytokine and its specific actions on ethanol consumption. For 
example, IL1rn (the gene that encodes IL-1Ra) knockout mice consumed less ethanol 
compared to their wild-type controls (Blednov et al., 2012). This is contrary to the general 
consensus that anti-inflammatories reduce ethanol consumption and could potentially be due 
to compensatory developmental adaptations stemming from lifelong constitutive deletion of 
the gene. The present study, however, shows the relevance of site-directed pharmacology 
and concurs with the general consensus that an anti-inflammatory state reduces ethanol 
consumption. The critical role of IL-1 signaling on alcohol-induced behaviors has also been 
shown, as peripheral IL-1Ra but not minocycline reduce ethanol-induced sedation (Wu et 
al., 2011). However, the data presented herein provide direct evidence that neuroimmune 
signaling, specifically BLA IL-1 signaling, regulates ethanol consummatory behaviors. IL-1 
receptor’s signaling effects on binge-like drinking were confined to the BLA as IL-1Ra had 
no effect in the adjoining CeA used as a site-directed control. The BLA also appeared to be 
particularly sensitive in terms of ethanol-induced changes in IL-1β immunoreactivity as no 
change was seen in the CeA. Importantly, the dose of IL-1Ra infused within the BLA had no 
independent effects on anxiety-like behavior or motor function according to data collected in 
the OFT. Moreover, the effect of IL-1Ra infusions appears to be specific to a function of 
ethanol as it had no bearing on sucrose consumption. IL-1 signaling within the BLA has also 
been shown to modulate heroin abuse indicating that the relationship between IL-1 signaling 
and the amygdala may not be unique to ethanol but may be involved in other drugs of abuse 
(Coller and Hutchinson, 2012; Szczytkowski and Lysle, 2008, 2010).
The present study shows an increase in a proinflammatory cytokine in a model of binge-like 
ethanol intake representing the early, more experimental stages of ethanol misuse in non-
dependent subjects (Thiele and Navarro, 2014). Human alcoholics and preclinical models 
indicate an increased proinflammatory state (Crews et al., 2011; He and Crews, 2008), but 
these findings were after a lifetime of alcohol abuse or in models with repeated binge 
exposure (Osterndorff-Kahanek et al., 2015; Qin and Crews, 2012b). However, what is 
unique about the present studies is that changes in IL-1β immunoreactivity and mRNA 
expression occurred prior to dependence and in subjects that were self-administering 
ethanol. Moreover, the alcohol-induced cytokine increase occurred at BECs well below 
those reported in previous acute and chronic studies, with BECs around 300mg/dL (Hayes et 
al., 2013; Qin and Crews, 2012a). Others have shown decreases in IL-1β expression 
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following a bolus ethanol intragastric challenge in rats after a period of abstinence agreeing 
with others who report that the timing of analysis can affect neuroimmune responses 
(Doremus-Fitzwater et al., 2014; Marshall et al., 2013). The findings herein, in respect to 
other studies on alcohol-induce alteration of IL-1β, indicate that changes in IL-1β occur 
during early ethanol consumption and at more moderate BECs than previously described. 
Importantly, our findings provide the first evidence that IL-1 signaling is recruited during 
excessive ethanol consumption and prior to dependence, and thus may play a critical role in 
modulating neuroplastic changes that occur during the transition to ethanol dependence.
Ethanol-induced upregulation of IL-1β mRNA expression observed within the amygdala 
persisted even in the absence of alcohol. These findings are in agreement with others 
showing ethanol elicited neuroimmune system dysfunction even a month after abstinence 
(Marshall et al., 2013). Persistent activation of glia and other neuroimmune responses can 
lead to exacerbated dysfunction in the presence of other immune challenges (Vetreno and 
Crews, 2014; Williamson et al., 2011). Moreover, the IL-1β mRNA response was initiated 
after just one cycle of DID, whereas the increase in protein expression was not significantly 
different until after three cycles. The strong trend of an increase after one week suggests that 
it does not necessarily take multiple binge exposures to increase the protein, but the 
possibility that there is a delayed response from just 1 cycle that causes the increase after 3 
cycles cannot be completely ruled out with the current data set. Regardless of when the 
IL-1β response is initiated, these studies highlight the enduring nature of increases in IL-1β 
mRNA in a model that represents the early stages of alcohol abuse. This plastic change is 
particularly alarming and suggests the neuroimmune response could be an early indicator of 
future addiction liability and may eventually contribute to cellular damage with repetitive 
exposure.
The persisting nature of the alcohol-induced neuroimmune response and the fact that it is 
proinflammatory led to the theory that alcohol-induced neuroimmune responses occur 
because of neurodegeneration but also potentially exacerbate damage (Crews et al., 2011; 
Vetreno and Crews, 2014). However, following multiple cycles of DID, this study indicates 
that neurodegeneration does not occur. The lack of cell death indicates that ethanol can elicit 
a neuroimmune response independent of significant brain damage. It is important to denote 
that the mechanism by which Fluoro-jade staining works is unknown, therefore it is 
perceivable that early stages of cellular death may not be incorporated in these cell counts 
(Poirier et al., 2000). However, very little FJC+ cells were expected to be induced by three 
cycles of DID as the BECs produced in the DID paradigm likely do not reach a level that 
would cause neurodegeneration (Liput et al., 2013). This is only the second paper to 
demonstrate that the DID paradigm does not elicit cellular damage (Sprow et al., 2015), but 
the first to use a marker of neurodegeneration. The enduring change of IL-1β mRNA 
without any neurodegeneration in this model further implicates IL-1 in a signaling role and 
not just as an indicator of cellular stress.
The underlying signaling pathways responsible for altered neurotransmission remain elusive 
with the current set of data. However, it has been previously shown that IL-1Ra can exert 
both indirect (glial driven) and direct (neuronal driven) control of glutamatergic 
transmission (Chu et al., 2010; De Chiara et al., 2013). In particular, glutamatergic 
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projections from the BLA, where IL-1 signaling had an effect on ethanol consumption, 
convey nociceptive information to the CeA (Veinante et al., 2013). Evidence suggests that 
CeA neuropeptides associated with nociception, such as CRF and NPY, modulate binge-like 
drinking (Lowery-Gionta et al., 2012; Sparrow et al., 2012; Veinante et al., 2013). Although 
these studies did not determine an effect of IL-1Ra administration in the CeA, recent 
evidence revealed that IL-Ra and IL-1β can regulate GABAergic transmission in response to 
ethanol in the CeA (Bajo et al., 2015a; Bajo et al., 2015b). Although Bajo and colleagues 
only examined the CeA, they suggest that the effects of IL-1 signaling in relation to alcohol-
induced GABAergic tone would likely be seen in other regions as well (Bajo et al., 2015a). 
While the studies herein show that IL-1Ra administration within the BLA reduced binge-
like drinking, it is perceivable that IL-1 receptor signaling in other regions include the CeA 
may have a different behavioral outcomes. Future studies are necessary to elucidate the 
underlying neurocircuitry and cell signaling cascades of IL-1 receptor signaling that 
contribute to binge-like drinking as well as other stages of AUD.
Alcoholism as with many drugs of abuse often develops after an experimental period. In 
alcohol misuse, the experimental period often includes binge drinking. The current findings 
provide evidence that binge-like consumption can alter the neuroimmune system prior to 
dependence or evidence of neuronal cell death. Furthermore, these results show that 
manipulating IL-1 signaling centrally modulates binge-like ethanol consumption. Together 
these findings with previous research indicate that the neuroimmune system remains a viable 
target for exploration in reducing binge-like drinking, but the impacts of other cytokine 
receptors, especially anti-inflammatory cytokines, in the amygdala as well as other regions 
of interests on ethanol consumption remain elusive.
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• Amygdalar IL-1β mRNA is increased for an extended period after binge-like 
drinking
• Alcohol-induced IL-1β increased immunoreactivity is specifically in the BlA
• Ethanol associated changes in IL-1β occurred independent of neurodegeneration
• IL-1R antagonist administration in the BlA but not CeA reduced ethanol 
consumption
• IL-1 receptor signaling in the amygdala has a role in binge-like drinking
Marshall et al. Page 15
Brain Behav Immun. Author manuscript; available in PMC 2017 January 01.
Author M
anuscript
Author M
anuscript
Author M
anuscript
Author M
anuscript
Figure 1. 
One cycle of DID induced increased mRNA expression of IL-1β when compared to the 
group that only received water. This effect persisted even a week into abstinence (*p<0.05 
compared to water group). All data are presented as mean ± SEM.
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Figure 2. 
Ethanol induced increased IL-1β immunoreactivity within the BLA after 3 cycles compared 
with the water control (A); however, no statistically significant difference was seen within 
the CEA between water and ethanol (C) or between water and sucrose were seen in either 
the BLA (B) or CEA (D; *p<0.05 compared to water group). Representative 
photomicrographs of the basolateral amygdala of mice exposed to water (E), 1 ethanol DID 
cycle (F), and 3 ethanol DID cycles (G) show an upregulation of IL-1β in the BLA. Scale 
bar in panel G= 20μm; dashed lines delineate the external capsule surrounding the 
basolateral amygdala. All data are presented as mean ± SEM.
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Figure 3. 
Neither ethanol (A,C) nor sucrose (B,D) induced any changes in FJC+ cells. Representative 
photomicrographs of the FJC stain for mice that received water (E) or underwent 1 (F) or 3 
(G) DID cycles of or ethanol show very little FJC+ cells. An LPS treated positive control 
can be seen in panel H. Scale bar in panel H= 20μm; dashed lines delineate the external 
capsule surrounding the basolateral amygdala. All data are presented as mean ± SEM.
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Figure 4. 
Graphs represent the collapsed data of the Latin-Square design. IL-1Ra pretreatment in the 
BLA resulted in reduced ethanol consumption (A) during the DID session and resulted in 
lower BECs (B) compared with saline. No significant effect of IL-1Ra manipulation within 
the CEA was observed in either consummatory data (C) or in BECs (D). Approximate 
injection sites are shown in panel E. Grey circles represent cannulae placement within the 
BLA while black circles represent those in the CeA. All data are presented as mean ± SEM.
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Figure 5. 
Collapsing across drug presentation groups, IL-1Ra administration in the BLA did not result 
in significant differences in sucrose consumption (A).Additionally IL-1Ra treatment in the 
BLA did not significantly affect locomotor activity (B) or any measures of anxiety [Center 
Time (C); Center Distance (D)]. Approximate injection sites are represented by grey circles 
in panel E. All data are presented as mean ± SEM.
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Table 1
ETHANOL INTAKE AND BLOOD ETHANOL LEVELS FROM THE mRNA, 
IMMUNOHISTOCHEMISTRY, AND FLUOROADE C EXPERIMENTS
Experiment Time Consumption (g/kg/4hr) BEC (mg/dL)
mRNA Expression
0d after 1-DID cycle 4.8±0.0.3 106.5±16.5
1d after 1-DID cycle 4.7±0.2 N/A
7d after 1-DID cycle 4.9±0.3 N/A
Immunohistochemistry
1-DID cycle 4.2±0.4 54.10±13.3
3-DID Cycles 4.7±0.4 91.33±16.3
Fluoro-Jade C
1-DID cycle 4.6±0.3 67.3±15.7
3-DID Cycles 4.5±0.3 71.9±16.3
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Table 2
CROSSING THRESHOLDS FOR qRT-PCR STUDY
Group β-Actin (Ct) IL-1β (Ct)
Water: 0D after 1-DID cycle 23.19 ± 0.3 37.35 ± 0.6
1d after 1-DID cycle 22.19 ± 0.4 37.05 ± 0.3
7d after 1-DID cycle 23.58 ± 0.4 37.07 ± 0.5
Ethanol 0D after 1-DID cycle 22.62 ± 0.3 34.27 ± 0.4
1d after 1-DID cycle 22.36 ± 0.2 34.77 ± 0.4
7d after 1-DID cycle 22.91 ± 0.4 35.49 ± 0.3
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